CBS-0550 is a drug developed by Taisho Pharmaceutical which acts as a potent and selective cannabinoid CB2 receptor agonist with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists CBS-0550 has good solubility in water and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.
This page contains content from the copyrighted Wikipedia article "CBS-0550"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
